Mohammad Javad Nasiri1, Hossein Dabiri2, Davood Darban-Sarokhalil3, Maryam Rezadehbashi4, Samin Zamani5. 1. Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: mj.nasiri@sbmu.ac.ir. 2. Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. 4. Chemical and Biological Engineering, University of British Columbia (UBC), Vancouver, BC, Canada. 5. Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
BACKGROUND: The spread of multidrug-resistant tuberculosis (MDR-TB) is a major public health problem worldwide. Although drug resistance is common in some countries and rare in others, the extent of this condition is not precisely known in Iran. METHODS: We searched several databases including PubMed, Web of Science, Scopus, Iran Medex, and Scientific Information Database to identify studies addressing drug-resistant tuberculosis in Iran. A total of 19 reports published from different regions of Iran from March 1999-May 2013 were included in this study. RESULTS: The meta-analyses revealed that 23% (95% confidence interval [CI], 21.8-24.2) of new cases and 65.6% (95% CI, 62.5-68.5) of previously treated cases were resistant to at least 1 drug. Furthermore, MDR-TB was found in 5.1% (95% CI, 4.4-5.8) of new cases, whereas it was found in 33.7% (95% CI, 30.8-36.7) of retreatment cases. The highest rate of resistance in new and previously treated cases was seen against streptomycin (19%) and isoniazid (47%), respectively. CONCLUSION: The results of the present study underscore the need for further enforcement of TB control strategies. Drug susceptibility testing, establishing advanced diagnostic facilities, and continuous monitoring of drug resistance are recommended for prevention and control of MDR-TB.
BACKGROUND: The spread of multidrug-resistant tuberculosis (MDR-TB) is a major public health problem worldwide. Although drug resistance is common in some countries and rare in others, the extent of this condition is not precisely known in Iran. METHODS: We searched several databases including PubMed, Web of Science, Scopus, Iran Medex, and Scientific Information Database to identify studies addressing drug-resistant tuberculosis in Iran. A total of 19 reports published from different regions of Iran from March 1999-May 2013 were included in this study. RESULTS: The meta-analyses revealed that 23% (95% confidence interval [CI], 21.8-24.2) of new cases and 65.6% (95% CI, 62.5-68.5) of previously treated cases were resistant to at least 1 drug. Furthermore, MDR-TB was found in 5.1% (95% CI, 4.4-5.8) of new cases, whereas it was found in 33.7% (95% CI, 30.8-36.7) of retreatment cases. The highest rate of resistance in new and previously treated cases was seen against streptomycin (19%) and isoniazid (47%), respectively. CONCLUSION: The results of the present study underscore the need for further enforcement of TB control strategies. Drug susceptibility testing, establishing advanced diagnostic facilities, and continuous monitoring of drug resistance are recommended for prevention and control of MDR-TB.
Authors: Mohammad Javad Nasiri; Abbas Ali Imani Fooladi; Hossein Dabiri; Ali Pormohammad; Alireza Salimi Chirani; Masoud Dadashi; Hamidreza Houri; Mohsen Heidary; Mohammad Mehdi Feizabadi Journal: Ther Adv Infect Dis Date: 2016-08-10
Authors: M J Nasiri; S Zamani; A Pormohammad; M M Feizabadi; H R Aslani; M Amin; R Halabian; A A Imani Fooladi Journal: Eur J Clin Microbiol Infect Dis Date: 2017-08-19 Impact factor: 3.267
Authors: Davood Darban-Sarokhalil; Mohammad J Nasiri; Abbas A I Fooladi; Parvin Heidarieh; Mohammad M Feizabadi Journal: Osong Public Health Res Perspect Date: 2016-04-06